CYP2C9 is essential for metabolizing warfarin and many NSAIDs. Variants in this gene significantly impact how you respond to blood thinners and require dosing adjustments.
Intermediate/Poor Metabolizer
Drug
Warfarin
Effect
Reduced metabolism → increased INR/bleeding risk
Recommendation
ADJUST. Lower dose. Frequent INR monitoring.
CPIC Guideline
CPIC Level A
FDA Label
FDA recommends PGx-guided dosing
Clinical Action: These recommendations are based on CPIC guidelines and FDA labeling. Discuss results with your healthcare provider or genetic counselor to determine appropriate treatment adjustments.
Know your CYP2C9 status? Get a personalized medication safety report.
Generate My Report